Cargando…

Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW

Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distribution of...

Descripción completa

Detalles Bibliográficos
Autores principales: Huisman, Lydian A., Steinkamp, Pieter J., Hillebrands, Jan-Luuk, Zeebregts, Clark J., Linssen, Matthijs D., Jorritsma-Smit, Annelies, Slart, Riemer H. J. A., van Dam, Gooitzen M., Boersma, Hendrikus H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858611/
https://www.ncbi.nlm.nih.gov/pubmed/33536498
http://dx.doi.org/10.1038/s41598-021-82568-8
_version_ 1783646635373363200
author Huisman, Lydian A.
Steinkamp, Pieter J.
Hillebrands, Jan-Luuk
Zeebregts, Clark J.
Linssen, Matthijs D.
Jorritsma-Smit, Annelies
Slart, Riemer H. J. A.
van Dam, Gooitzen M.
Boersma, Hendrikus H.
author_facet Huisman, Lydian A.
Steinkamp, Pieter J.
Hillebrands, Jan-Luuk
Zeebregts, Clark J.
Linssen, Matthijs D.
Jorritsma-Smit, Annelies
Slart, Riemer H. J. A.
van Dam, Gooitzen M.
Boersma, Hendrikus H.
author_sort Huisman, Lydian A.
collection PubMed
description Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distribution of VEGF-A in (non-)culprit carotid plaques ex vivo. Freshly endarterectomized human plaques (n = 15) were incubated in bevacizumab-800CW ex vivo. Subsequent NIRF imaging showed a more intense fluorescent signal in the culprit plaques (n = 11) than in the non-culprit plaques (n = 3). A plaque received from an asymptomatic patient showed pathologic features similar to the culprit plaques. Cross-correlation with VEGF-A immunohistochemistry showed co-localization of VEGF-A over-expression in 91% of the fluorescent culprit plaques, while no VEGF-A expression was found in the non-culprit plaques (p < 0.0001). VEGF-A expression was co-localized with CD34, a marker for angiogenesis (p < 0.001). Ex vivo near-infrared fluorescence (NIRF) imaging by incubation with bevacizumab-800CW shows promise for visualizing VEGF-A overexpression in culprit atherosclerotic plaques in vivo.
format Online
Article
Text
id pubmed-7858611
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78586112021-02-04 Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW Huisman, Lydian A. Steinkamp, Pieter J. Hillebrands, Jan-Luuk Zeebregts, Clark J. Linssen, Matthijs D. Jorritsma-Smit, Annelies Slart, Riemer H. J. A. van Dam, Gooitzen M. Boersma, Hendrikus H. Sci Rep Article Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distribution of VEGF-A in (non-)culprit carotid plaques ex vivo. Freshly endarterectomized human plaques (n = 15) were incubated in bevacizumab-800CW ex vivo. Subsequent NIRF imaging showed a more intense fluorescent signal in the culprit plaques (n = 11) than in the non-culprit plaques (n = 3). A plaque received from an asymptomatic patient showed pathologic features similar to the culprit plaques. Cross-correlation with VEGF-A immunohistochemistry showed co-localization of VEGF-A over-expression in 91% of the fluorescent culprit plaques, while no VEGF-A expression was found in the non-culprit plaques (p < 0.0001). VEGF-A expression was co-localized with CD34, a marker for angiogenesis (p < 0.001). Ex vivo near-infrared fluorescence (NIRF) imaging by incubation with bevacizumab-800CW shows promise for visualizing VEGF-A overexpression in culprit atherosclerotic plaques in vivo. Nature Publishing Group UK 2021-02-03 /pmc/articles/PMC7858611/ /pubmed/33536498 http://dx.doi.org/10.1038/s41598-021-82568-8 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Huisman, Lydian A.
Steinkamp, Pieter J.
Hillebrands, Jan-Luuk
Zeebregts, Clark J.
Linssen, Matthijs D.
Jorritsma-Smit, Annelies
Slart, Riemer H. J. A.
van Dam, Gooitzen M.
Boersma, Hendrikus H.
Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_full Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_fullStr Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_full_unstemmed Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_short Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_sort feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800cw
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858611/
https://www.ncbi.nlm.nih.gov/pubmed/33536498
http://dx.doi.org/10.1038/s41598-021-82568-8
work_keys_str_mv AT huismanlydiana feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT steinkamppieterj feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT hillebrandsjanluuk feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT zeebregtsclarkj feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT linssenmatthijsd feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT jorritsmasmitannelies feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT slartriemerhja feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT vandamgooitzenm feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
AT boersmahendrikush feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw